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Abstract
Mitochondrial proteases are key components in mitochondrial stress responses that maintain proteostasis and
mitochondrial integrity in harsh environmental conditions, which leads to the acquisition of aggressive phenotypes,
including chemoresistance and metastasis. However, the molecular mechanisms and exact role of mitochondrial
proteases in cancer remain largely unexplored. Here, we identified functional crosstalk between LONP1 and ClpP,
which are two mitochondrial matrix proteases that cooperate to attenuate proteotoxic stress and protect
mitochondrial functions for cancer cell survival. LONP1 and ClpP genes closely localized on chromosome 19 and were
co-expressed at high levels in most human cancers. Depletion of both genes synergistically attenuated cancer cell
growth and induced cell death due to impaired mitochondrial functions and increased oxidative stress. Using
mitochondrial matrix proteomic analysis with an engineered peroxidase (APEX)-mediated proximity biotinylation
method, we identified the specific target substrates of these proteases, which were crucial components of
mitochondrial functions, including oxidative phosphorylation, the TCA cycle, and amino acid and lipid metabolism.
Furthermore, we found that LONP1 and ClpP shared many substrates, including serine hydroxymethyltransferase 2
(SHMT2). Inhibition of both LONP1 and ClpP additively increased the amount of unfolded SHMT2 protein and
enhanced sensitivity to SHMT2 inhibitor, resulting in significantly reduced cell growth and increased cell death under
metabolic stress. Additionally, prostate cancer patients with higher LONP1 and ClpP expression exhibited poorer
survival. These results suggest that interventions targeting the mitochondrial proteostasis network via LONP1 and ClpP
could be potential therapeutic strategies for cancer.
Introduction
Mitochondria are intracellular organelles that produce
the majority of energy in cells by synthesizing ATP via
oxidative phosphorylation. Beyond cellular bioenergetics,
mitochondria have many other functions including reg-
ulation of redox balance, metabolite biosynthesis, reg-
ulation of calcium homeostasis, and modulation of cell
death pathways1,2. Therefore, mitochondria homeostasis
is tightly regulated. Cancer cells rely heavily on
mitochondria to meet their high energy demands and
generate macromolecules used as building blocks to fuel
rapid cancer cell proliferation1,3,4. Additionally, mito-
chondria serve as a central signaling hub that integrates
extracellular and intracellular signaling pathways and
nutrient status controlling epigenetics, stemness, cell
cycle regulation, and apoptosis and are thus involved in all
phases of cancer initiation, progression, and metastasis5–
7,8. Therefore, mitochondria have emerged as a ther-
apeutic target for novel anticancer agents9,10.
As cancer cells are continuously exposed to various
cytotoxic stressors in harsh tumor microenvironments,
including hypoxia, nutrient deprivation, and oxidative
stress, mitochondria must adapt to changes and buffer
stress conditions to promote cancer cell proliferation and
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survival11,12. Indeed, mitochondrial stress responses
are linked to alterations in mitochondrial functions
required for tumor progression via adaptations to chan-
ging metabolic demands, regulation of cell death
pathways, and contributions to chemoresistance4. One
well-characterized cytoprotective mitochondrial stress
response pathway is the protein quality control system,
which maintains mitochondrial protein homeostasis by
degrading misfolded and aggregated proteins to buffer
proteotoxic stress associated with stressful conditions13.
Different from the ubiquitin/proteasome system for
cytosolic protein homeostasis, mitochondrial chaperone
and protease proteins are crucial for mitochondrial pro-
teostasis, are overexpressed in most tumor types, and are
involved in metabolic reprogramming that allows evasion
of apoptosis and increased survival14,15,16. However, the
molecular mechanisms regulating mitochondrial pro-
teostasis and its exact function in cancer remain largely
unknown.
Among the effectors of mitochondrial proteostasis,
mitochondrial matrix serine proteases Lon protease
(LONP1) and caseinolytic peptidase P (ClpP) are key
inducers of mitochondrial protein quality control for the
clearance of misfolded or damaged proteins, which is
necessary for maintaining mitochondrial functions. Ele-
vated activities of these two proteases are correlated with
tumor development and progression17,18,15. These pro-
teases may modulate cancer cell viability, reactive oxygen
species (ROS) levels, and metabolic reprogramming under
hypoxia, oxidative stress, or starvation14. Consequently,
inhibition or hyperactivation of these proteases may be a
potential therapeutic strategy for cancer18. Although
LONP1 and ClpP exert similar actions in cancer, their
regulatory mechanisms and potential interconnections
remain largely unexplored. Here, we identified the specific
target substrates of each protease and discovered func-
tional crosstalk through which LONP1 and ClpP coop-
eratively modulate aspects of mitochondrial proteostasis
that are crucial for cancer cell growth and survival. These
findings suggest that targeting the interplay between




Antibodies against ClpP (Abcam, Cambridge, MA, USA,
#ab124822), LONP1 (Novus Biologicals, Centennial, CO,
USA, #NBP1-81734), beta-actin (GeneTex, San Antonio,
TX, USA, #GTX109639), cleaved PARP (Cell Signaling,
Danvers, MA, USA, #9541), PARP (Cell Signaling, #9532),
Thr172-phosphorylated AMPK (Cell Signaling, #2531),
AMPK (Cell Signaling, #2630), LC3B (Cell Signaling,
#2775), HRP-conjugated streptavidin (Sigma Aldrich, St.
Louis, MO, USA #RABHRP3), SHMT2 (Atlas Antibodies,
Bromma, Stockholm, Sweden, #HPA020549), SHMT1
(Santa Cruz Biotechnology, Santa Cruz, CA, USA, sc-
365203), Ser555-phosphorylated ULK1 (Cell Signaling,
#5869 S), ULK1 (Cell Signaling, #9661), p62/SQSTM1
antibodies (Santa Cruz Biotechnology, sc-28359), TUFM
(Abcam, #ab175199), PDK1 (Abcam, #ab110025), ATP5B
(Abcam, #ab14730), FH (Abcam, #ab191367), SSBP1
(Proteintech, Chicago, IL, USA, #12212-1-AP), VDAC
(Abcam, #ab14734), and alpha-tubulin (GeneTex,
#GTX112141) were used for western blotting. (+)-SHIN1
was from MedChmexpress (Princeton, NJ, USA, #HY-
112066A). MitoTracker Red (#M7512) and MitoSOX Red
(#M36008) were from Invitrogen. Sequencing-grade
trypsin, sodium azide, sodium ascorbate, and Trolox
were from Sigma Aldrich (St. Louis, MO, USA). Plasmids
for APEX fusion constructs for targeting mitochondria
(mito-APEX) and biotin-phenol were provided by Prof.
Hyun-Woo Rhee (Seoul National University, Seoul,
Korea).
Cell culture
Human prostate adenocarcinoma LNCaP, PC3, DU145,
22RV1, C4-2, and C4-2B cells; normal prostate epithelial
RWPE1 cells; benign prostatic hyperplasia epithelial BPH-
1 cells; human glioblastoma LN229 cells; and human
colorectal carcinoma HCT116 and SW480 cells; human
embryonic kidney 293 (HEK-293) cells were obtained
from the American Type Culture Collection (ATCC,
Manassas, VA, USA). All cell lines were maintained in
culture according to the supplier’s recommendations. For
glucose starvation experiments, cells were cultured in
glucose deprived-RPMI 1640 medium (Gibco, Gaithers-
burg, MD, USA, #11879-020) supplemented with glucose
(0.5 or 1 mM) and 2% fetal bovine serum. Cells were
incubated for 24 h.
Transfections
To knock down LONP1 and ClpP by siRNA, cancer cell
lines were transfected with non-targeting siRNA (Dhar-
macon, Lafayette, CO, USA, #D-001210), siRNA pools
targeting LONP1 (Dharmacon, #L-003979-00-0020), or
custom-prepared ClpP-directed siRNA with the sequence
GUUUGGCAUCUUAGACAAGGUUCUGUU. siRNAs
were transfected at 20 nM in the presence of lipofecta-
mine RNAiMAX (Invitrogen, Carlsbad, CA, USA) at a
1:1.5 ratio. Cells were incubated for 48 h, validated for
target protein knockdown by western blotting, and pro-
cessed for subsequent experiments.
Quantitative RT-PCR analysis
Total RNA was extracted with TRIzol (Ambion, Austin,
TX, USA) according to the manufacturer’s instructions.
RNA (2 μg) was reverse-transcribed using a high-capacity
cDNA reverse transcription kit (Applied Biosystems,
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Foster City, CA, USA). Equal amounts of cDNA for each
sample were mixed with Prime Q-Mastermix (Genet Bio,
Chungnam, Korea). qRT-PCR reactions were performed
in a Light Cycler 480 system (Roche Applied Science,
Mannheim, Germany). The following real-time quantita-
tive PCR primers were used: LONP1: forward, 5′-ATGG
AGGACGTCAAGAAACG-3′ and reverse, 5′-GAC
GCTGAAGCGGAAGTACTC-3′; ClpP: forward, 5′-TTG
CCAGCCTTGTTATCGCA-3′ and reverse, 5′-GGTTG
AGGATGTACTGCATCG-3′; SHMT2: forward, 5′-TCG
GAGGGTTATCCTGGCAA-3′ and reverse, 5′-TTTAGG
GCCACAGCTACTGC-3′; GAPDH: forward, 5′-GAAGG
TGAAGGTCGGAGTC-3′ and reverse, 5′-GAAGATGGT
GATGGGATTTC-3′. ATF4: forward, 5′-CCAACAAC
AGCAAGGAGGAT-3′ and reverse, 5′-GGGGCAAAG
AGATCACAAGT-3′; ATF6: forward, 5′-TGACAAA
GCCCTGATGGTGCTA-3′ and reverse, 5′-TGTTCCAG
AGCACCCTGAAGAA-3′; CHOP: forward, 5′-GGAG
AACCAGGAAACGGAAAC-3′ and reverse, 5′-TCTC
CTTCATGCGCTGCTTT-3′. mRNA levels were nor-
malized to GAPDH mRNA level as a control and calcu-
lated according to the ΔΔCt method.
Protein analysis
Cells were washed twice with cold phosphate-buffered
saline (PBS) and lysed with RIPA buffer (150 mM NaCl,
1.0% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS,
50 mM Tris, pH 8.0) containing protease and phospha-
tase inhibitor cocktail (Invitrogen). Equal amounts of
protein lysates were separated by SDS gel electrophoresis,
transferred to a PVDF membrane, and incubated with
primary antibodies. After incubation with horseradish
peroxidase-conjugated secondary antibodies (Santa Cruz
Biotechnology), protein bands were visualized by che-
miluminescence. Densitometry was performed using
ImageJ software.
Mitochondrial DNA levels
DNA was isolated from LNCaP or DU145 cells using
a DNA Purification Kit (Macherey-Nagel, Duren, Ger-
many). The ratio of mitochondrial DNA (mtDNA) to
genomic DNA was determined by performing qPCR
with nDNA β2-microglobulin (forward, TGCTGTCT
CCATGTTTGATGTATCT; reverse, TCTCTGCTCC
CCACCTCTAAGT), MT-ATP6 (forward, TAGCCAT
ACACAACACTAAAGGACGA; reverse, GGGCATTT
TTAATCTTAGAGCGAAA), and MT-CYB (forward,
ATCACTCGAGACGTAAATTATGGCT; reverse, TG
AACTAGGTCTGTCCCAATGTATG) primers. All
primer pairs were run in individual reactions. The final
mtDNA/nucDNA ratio for each sample was calculated
by averaging the ratio obtained from each primer pair.
Expression data were analyzed with the ΔΔCt method.
Mitochondrial protein folding
Mitochondrial protein folding assay was carried out as
previously described19. LNCaP or DU145 cells were
transfected with control non-targeting siRNA or LONP1
and/or ClpP-directed siRNA for 48 h. Mitochondrial
fractions were prepared using a mitochondria isolation kit
(BioVision Milpitas, CA, USA #K256-25) following the
manufacturer’s recommendations. Briefly, cells were
mechanically disrupted by 70 strokes in a Dounce
homogenizer in isolation buffer A containing protease
inhibitor cocktail. Cell debris and nuclei were removed by
centrifugation at 700 g for 10 min, and mitochondrial
fractions were precipitated by centrifugation at 3000 g for
25 min. To obtain highly enriched mitochondrial frac-
tions, samples were subject to another round of cen-
trifugation at 12,000 g for 10 min in isolation buffer C, and
the final pellet was used as an isolated mitochondrial
fraction. Mitochondrial fractions were suspended in an
equal volume of mitochondrial fractionation buffer con-
taining increasing concentrations of CHAPS (0, 1, or
2.5%). Samples were incubated for 20min on ice, and
detergent-insoluble protein aggregates were recovered by
centrifugation (20,000 g) for 20 min. Pelleted proteins
were separated by SDS gel electrophoresis and visualized
by SYPRO Ruby staining (Invitrogen).
Colony formation
LNCaP or DU145 cells (5 × 103 cells per well) trans-
fected with control non-targeting siRNA or LONP1 and/
or ClpP-directed siRNA for 48 h or treated with vehicle or
SHIN1 (0–10 μM) were plated in triplicate in 6-multiwell
plates. After 7–10 days, colonies were washed in PBS and
fixed/stained for 30min in 0.5% w/v crystal violet/
methanol. Plates were rinsed in tap water and dried before
scoring. Macroscopically visible colonies were manually
counted.
ATP production
ATP concentration in cells was measured using an
ATP Assay kit (BioChain, Newark, CA, USA
#Z5030041). Briefly, cells (1 × 104) were seeded in 96-
well white plates in complete media and incubated for
1 day at 37 °C. Culture media was removed, and a
reaction mixture was added immediately. To quantify
ATP production, luminescence was measured within
1 min. Individual values were normalized by cell num-
ber per well.
ROS production
Mitochondrial superoxide production was visualized by
fluorescence microscopy. Briefly, cells (2 × 104) trans-
fected with control non-targeting siRNA or LONP1 and/
or ClpP-directed siRNA for 48 h were reseeded on high
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optical quality 8-well μ-slides (Ibidi) and stained with
MitoSOX Red mitochondrial superoxide indicator (5 μM,
10min) in complete medium. Stained cells were imaged
with a ×40 objective on a Nikon TE300 inverted
time-lapse microscope equipped with a video system
containing an Evolution QEi camera and time-lapse video
cassette recorder. The atmosphere was equilibrated to
37 °C and 5% CO2 in an incubation chamber. Phase and
red fluorescence (TRITC filter cube, excitation wave-
length: 532–554 nm, emission wavelength: 570–613 nm)
images were captured. To quantify superoxide levels, an
equal number of stained cells (1 × 104 in 100 μL) were
suspended in PBS, and fluorescence (Ex/Em: 510/580 nm)
was measured immediately.
Proteome mapping for mitochondrial proteins by APEX-
mediated biotinylation
Labeling of the mitochondrial matrix proteome in cells
was performed as previously described20,21. Briefly, mito-
APEX was transfected into LNCaP cells. After 24 h, cells
were transfected with control non-targeting siRNA or
LONP1 or ClpP-directed siRNA for 48 h. The medium was
changed to 1mL serum-free medium containing biotin-
phenol (500 μM) for 30min at 37 °C. Then, H2O2 (final
concentration, 1mM) was added for 1min to initiate bio-
tinylation. The reaction was terminated by the addition of a
quencher solution containing 10mM sodium azide, 10mM
sodium ascorbate, and 5mM Trolox in Dulbecco’s PBS
(DPBS). For streptavidin blotting, cells were lysed with
RIPA buffer containing quencher solution and protease and
phosphatase inhibitor cocktail (Invitrogen). Lysates were
transferred to an e-tube and clarified by centrifugation at
15,000 g for 10min at 4 °C before separation on a 10% SDS-
PAGE gel. The gel was transferred to a nitrocellulose
membrane and blocked with 2% (w/v) dialyzed BSA (dBSA)
in TBST at room temperature for 1 h. The blots were
immersed in streptavidin-HRP in 2% dialyzed BSA in TBST
at room temperature for 30–60min and then rinsed with
TBST before development and imaging by chemilumines-
cence. For imaging analysis, cells were stained with 100 nM
MitoTracker Red Reagent (Invitrogen) for 30min at 37 °C
according to the manufacturer’s instructions. Cells were
then fixed with 4% paraformaldehyde solution in DPBS for
15min, washed with DPBS three times, and permeabilized
with cold MeOH for 5min. After three washes with DPBS,
cells were blocked for 1 h with dBSA in DPBS. Cells were
stained with anti-V5 (Invitrogen) in blocking buffer for 1 h
to detect mito-APEX expression. After washing four times
with TBST, cells were incubated with secondary goat anti-
mouse-AF antibody (Invitrogen) in blocking buffer for 1 h.
Samples were washed with PBS four times and maintained
in DPBS at room temperature for imaging. Imaging was
performed in confocal mode using a confocal microscope
(ZEISS, LSM780).
For proteomic mapping by liquid chromatography-mass
spectrometry analysis, cell lysates were sonicated, and
proteins were precipitated with cold acetone for 2 h twice.
After drying the pellet, proteins were dissolved with 8M
urea and denatured for 1 h at 37 °C with shaking. Proteins
were reduced with 10 mM DTT in 50mM ammonium
bicarbonate (ABC) for 1 h. DTT solution was subse-
quently removed, and proteins were incubated in 40mM
iodoacetamide in 100mM ABC for 1 h with shaking in the
dark. The sample solution was diluted with 50 mM ABC
until reaching 1M urea, after which 1M CaCl2 was added
(final concentration, 1 mM). Trypsin (10 µL of 20 ng/µL)
was added to 5 µg protein samples, and digestion was
completed overnight with shaking at 37 °C. After
overnight digestion, excess trypsin solution was removed
from each sample, and samples were incubated with
streptavidin-coated magnetic beads (Invitrogen, #11205D)
for 1 h with gentle rotation. Streptavidin beads were
washed twice with 2M urea in 50mM ABC. Biotinylated
proteins were eluted from magnetic streptavidin beads
with elution buffer (acetonitrile/TFA/formic acid/H2O=
80:0.2:0.1:19.7, v/v/v) for 5 min at 60 °C five times. Com-
bined extracts were dried to completeness in a vacuum
concentrator, reconstituted in 0.1% formic acid/3% acet-
onitrile, and analyzed as previously described21.
Bioinformatics meta-analysis
Comparison of expression patterns for LONP1 and
ClpP was performed using cancer databases from TCGA
(http://tcga-data.nci.nih.gov/tcga/) and the online Uni-
versity of California Santa Cruz Xena browser (http://
xena.ucsc.deu/). Kaplan–Meier analysis was based on the
TCGA PRAD database, and a log-rank (Mantel–Cox) test
was performed to evaluate statistical significance.
Quantification and statistical analysis
All statistical analyses were performed using GraphPad
Prism 7. Data are shown as the mean ± standard deviation
(SD) of two or three independent experiments. A p-value
of ≤0.05 was considered statistically significant. Pearson’s
correlation coefficients (r) were used to calculate the
correlation between LONP1 and ClpP. Survival was
assessed using the Kaplan–Meier method and log-
rank test.
Results
LONP1 and ClpP are highly co-expressed in multiple
human cancers
To investigate relationships between the two proteases,
we first analyzed patterns of LONP1 and ClpP expression
in various cancer types from The Cancer Genome Atlas
(TCGA) database. RNA expression of both LONP1 and
ClpP were significantly upregulated in a wide range of
human cancers, including bladder, breast, colon, kidney,
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lung, thyroid, uterine, and prostate cancer, compared with
normal tissue (Fig. 1A). Interestingly, their expression
pattern was markedly similar across cancer types (Fig. 1B).
In addition, in the Cancer Cell Line Encyclopedia (CCLE)
database containing 1457 cancer cell lines, median ClpP
expression was the highest in prostate cancer, and LONP1
expression was also highly elevated in prostate cancer
relative to other cancer types (Fig. S1). Given the similar
Fig. 1 Co-expression of ClpP and LONP1 in human cancers. A mRNA expression of ClpP (upper) and LONP1 (bottom) were compared between
multiple tumor types and paired normal tissue from the TCGA database. Data are shown as a box and whisker plot using the Tukey method.
Student’s t-tests were used to evaluate statistical significance. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, n.s., not significant. B Heatmap
showing summary mRNA expression profiles of ClpP and LONP1 in multiple tumor types with statistical significance (p < 0.05) (cancer vs. normal, red:
upregulation; blue: downregulation). C Protein levels of ClpP and LONP1 in cell lines analyzed by western blotting. D Co-expression analysis of ClpP
and LONP1. mRNA expression values from RNA Seq FPKM data from the TCGA PCa database (n= 498). Pearson correlation coefficients (r) and p-
values (p) are presented. E Co-expression analysis of ClpP and LONP1 in multiple cancer types with statistical significance (p < 0.05) from the TCGA
database. Pearson correlation coefficients (r), p-values (p), and number of patients (n) are presented. F Frequency of genomic gains/amplifications
(orange, up) and deletions (blue, down) across all chromosomes from 1,323 prostate cancer samples shown in a Progenetix histoplot. The genomic
locus of LONP1 and ClpP genes are marked by arrowheads.
Lee et al. Oncogenesis           (2021) 10:18 Page 5 of 14
Oncogenesis
elevated expression patterns of these two mitochondrial
proteases in tumor tissue compared with normal tissue,
we hypothesized that co-expression of these two proteases
is associated with cancer progression. In agreement with
mRNA data, LONP1 and ClpP proteins were highly co-
expressed in prostate cancer compared with non-
transformed prostate cells, including RWPE1 and
BPH1 cells (Fig. 1C). Furthermore, LONP1 and ClpP
mRNA expression were strongly positively correlated in
prostate cancer patient samples as well as most other
cancer samples (Fig. 1D, E; Fig. S2), whereas human m-
AAA protease AFG3L2 had no correlation with LONP1
and ClpP (Fig. S3). Interestingly, LONP1 and ClpP genes
closely localized to chromosomal region 19 (19q13), and
the genomic locus of these two genes frequently exhibited
gain in prostate cancer patient samples (Fig. 1F). This
finding that LONP1 and ClpP are highly co-expressed in
various human cancers suggests a functional link between
the two mitochondrial proteases in cancer.
Inhibition of LONP1 and ClpP additively leads to cancer
cell death
Inhibition of LONP1 and ClpP separately reduces cancer
growth and viability22,14. To assess whether co-expression
of these two proteases plays a role in cancer, we examined
whether LONP1 and ClpP downregulation jointly impact
the proliferation of prostate cancer cells. Separate knock-
down of LONP1 or ClpP genes with small interfering RNA
(siRNA) reduced the growth of prostate cancer cells,
including LNCaP, C4-2B, DU145, and PC3 cells. However,
the simultaneous knockdown of LONP1 and ClpP reduced
cell growth more than a single knockdown and caused cell
death, as evidenced by increased PARP cleavage (Fig. 2A,
B). To confirm these results, we performed the colony
formation assay and observed that the simultaneous
knockdown of both genes significantly reduced colony
formation (Fig. 2C). Conversely, the silencing of LONP1
and ClpP did not affect the growth of the non-cancerous
cell lines BPH-1 and HEK-293, which had lower levels of
LONP1 and ClpP than those in cancer cells (Fig. S4).
Consistently, prostate cancer patients with high levels of
both LONP1 and ClpP expression showed significantly
worse survival outcomes than those with only high LONP1
or ClpP expression (Fig. 2D). Together, these findings
further indicate a link between LONP1 and ClpP function
in cancer cell proliferation and viability.
LONP1 and ClpP maintain mitochondrial functions and cell
survival under stress conditions
We next investigated the role of LONP1 and ClpP co-
expression in the regulation of mitochondrial function.
Knockdown of LONP1 or ClpP in LNCaP or DU145 cells
led to increased phosphorylation of the energy sensor 5’-
adenosine monophosphate-activated protein kinase
(AMPK), indicating defective mitochondrial bioener-
getics23,24 (Fig. 3A, Fig. S5). In turn, autophagy, a down-
stream pathway of AMPK signaling, was upregulated by
LONP1 or ClpP knockdown, as evidenced by the phos-
phorylation of ULK1, reduction in p62, and LC3-II
accumulation. In addition, LONP1 or ClpP knockdown
increased the protein or mRNA expression of
mitochondrial-UPR (mito-UPR) genes, including CHOP,
Hsp60, ATF4, and ATF6 (Fig. S6). However, the double
knockdown of LONP1 and ClpP increased AMPK phos-
phorylation, mito-UPR, and autophagy more than single
knockdowns (Fig. 3A, Figs. S5, S6). Consistently, the
depletion of LONP1 or ClpP reduced ATP production
(Fig. 3B) and increased mitochondrial ROS production
(Fig. 3C, D), whereas normal cells were not affected (Fig.
S4D, E). LONP1 and ClpP silencing did not affect the total
mitochondrial content (Fig. S7). In addition, AMPK
phosphorylation, autophagy, and mito-UPR pathway
activity, and ROS production were further increased after
the simultaneous silencing of both genes. Considering the
pro-survival roles of LONP1 and ClpP, we next evaluated
LONP1- and ClpP-mediated mitochondrial protease
requirements for cancer cell adaptation to metabolic
stressors, such as starvation and oxidative stress. Deple-
tion of LONP1 or ClpP increased cell sensitivity to
metabolic stress induced by oxidative stress (H2O2; Fig.
3E) or starvation (low glucose; Fig. 3F), and this cell
sensitivity was further increased by simultaneous knock-
down of both genes. These findings suggest that LONP1
and ClpP cooperatively modulate mitochondrial function
in cancer cell survival.
LONP1 and ClpP regulate mitochondrial protein folding
and proteostasis
The function of mitochondrial proteases is determined
by maintaining protein quality through the specific pro-
teolysis of damaged proteins. To investigate the molecular
mechanisms by which LONP1 and ClpP regulate mito-
chondrial function, we characterized LONP1- and ClpP-
specific substrates. We first examined the impact of
LONP1 and ClpP depletion on mitochondrial protein
homeostasis. siRNA silencing of LONP1 and ClpP in
LNCaP cells resulted in the accumulation of detergent-
insoluble proteins, indicating accumulation of aggregated
and misfolded proteins (Fig. 4A). Based on this finding, we
identified potential substrates of proteases by measuring
levels of upregulated proteins in the detergent-insoluble
fraction after LONP1 and ClpP depletion with compre-
hensive proteomic analysis19. We also applied the
mitochondrial matrix-targeted ascorbate peroxidase
(mito-APEX) labeling method to probe the spatial
mitochondrial matrix proteome (Fig. S8)25,21. We tran-
siently expressed mito-APEX in LNCaP cells and con-
firmed that mito-APEX was specifically expressed in
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mitochondria and that endogenous proteins were bioti-
nylated by mito-APEX (Fig. 4B and C). Mitochondria
matrix proteins were purified using streptavidin beads and
quantified by mass spectrometry analysis. In total, all 144
mitochondrial matrix proteins were detected. Of these, 72
proteins showed increased levels (≥1.5-fold change) in
spectral counts (p < 0.05) following knockdown of LONP1
and ClpP (Fig. 4D), indicating a requirement of LONP1
and ClpP for specific proteolysis. Subsequently, 42 pro-
teins (58.3% of total) were commonly upregulated by
Fig. 2 Inhibition of ClpP and LONP1 attenuates cancer cell growth and induces cell death. A, B Prostate cancer cell lines (LNCaP, C4–2B,
DU145, and PC3) were transfected with control non-targeting siRNA (siCtrl) or LONP1 (siLONP1) and/or ClpP-directed siRNA (siClpP) for 72 h. A Cell
proliferation was measured by direct cell counting. Mean ± SD (n= 3). *p < 0.01, **p < 0.001, ***p < 0.0001. B Total cell lysates were analyzed by
western blotting for full-length and cleaved PARP protein levels as an apoptotic marker. Clv, cleaved. Densitometric quantification of bands in cleaved
PARP was normalized with bands in total PARP (bottom). Data from three independent experiments are shown. Mean ± SD (n= 3). *p < 0.01, **p <
0.001, ***p < 0.0001. C LNCaP and DU145 cells were transfected with siCtrl or siLONP1 and/or siClpP for 48 h and reseeded in 6-well plates. Colony
formation was assessed by crystal violet staining after 7 days and quantified (bottom). Data from three independent experiments are shown. Mean ±
SD (n= 3). **p < 0.001, ***p < 0.0001. D Kaplan–Meier recurrence-free survival of patients from the TCGA prostate cancer database (n= 471).
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Fig. 3 ClpP and LONP1 protect mitochondria functions required for cell survival under stress conditions. A–F LNCaP and DU145 cells were
transfected with control non-targeting siRNA (siCtrl) or LONP1 (siLONP1) and/or ClpP-directed siRNA (siClpP) for 72 h. A Total cell lysates were
analyzed by western blotting for phosphorylation of AMPK (Thr172) and ULK1 (Ser555), p62 and LC3-I/II. p, phosphorylated. B ATP production.
C Mitochondrial ROS levels. Data representative of three independent experiments are shown. Mean ± SD (n= 3). *p < 0.05, **p < 0.01, ***p < 0.001.
D Representative images of MitoSOX Red (for mitochondrial superoxide) and MitoTracker Green (for mitochondrial content) fluorescence. Scale bar =
5 µm. Quantitative analysis of fluorescence intensity is shown in the right panel. Integrated pixel intensities from MitoSOX Red signals were
normalized by the area occupied by MitoTracker Green. Whole images and 40 cells per group were used for calculations. Data are shown as mean ±
SD of individual cells. ***p < 0.001. E, F DU145 cells were transfected with siCtrl or siLONP1 and/or siClpP for 48 h. Cells were incubated in (E) H2O2
(100 μM) or (F) low glucose (0.5 mM) for 24 h. Cell proliferation was measured by direct cell counting. Mean ± SD (n= 3). **p < 0.001, ***p < 0.0001,
n.s., not significant.
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silencing of LONP1 or ClpP, indicating that LONP1 and
ClpP share substrate proteins (Fig. 4D and E). Among the
substrates displaying large increases were components of
oxidative phosphorylation, the TCA cycle, and lipid or
amino acid metabolism, and the substrate with the most
robust increase was serine hydroxymethyltransferase-2
Fig. 4 (See legend on next page.)
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(SHMT2), which is a key regulator of serine metabolism
in mitochondria (Fig. 4E). These results suggest that ClpP
and LONP1 selectively but cooperatively modulate
mitochondrial proteostasis.
SHMT2 is a common substrate of ClpP and LONP1
proteases
To confirm our proteomic results, we analyzed protein
levels of substrate targets for LONP1 and ClpP by western
blotting with specific antibodies against several proteins
including SHMT2, pyruvate dehydrogenase kinase 1
(PDK1), ATP synthase subunit β (ATP5B), and fumarate
hydratase (FH) (Fig. 5A and Fig. S9). The silencing of
LONP1 or ClpP increased these protein levels, particu-
larly SHMT2, which was significantly increased following
the silencing of both genes (Fig. 5A). An increase in the
SHMT2 level by LONP1 and ClpP knockdown was also
observed in DU145 cells, whereas the expression level of
cytosolic SHMT1 was not affected (Fig. 5B, C; Fig. S10).
Next, we examined the folding status of substrate proteins
in the absence of LONP1 and ClpP. We found that
knockdown of LONP1 or ClpP selectively induced accu-
mulation of misfolded or aggregated SHMT2 and ATP5B
at different CHAPS concentrations (Fig. 5D, E) under the
same conditions. These results suggest that LONP1 and
ClpP selectively and cooperatively regulate SHMT2 pro-
tein quality by degrading unfolded SHMT2 proteins.
LONP1- and ClpP-directed SHMT2 protein homeostasis is
required for cancer cell survival
Serine is a central hub of cancer metabolism that sus-
tains cell growth and proliferation26. Also, upregulation of
SHMT2 and its association with tumor progression is
reported for several types of cancer27,28,29. Therefore, we
examined whether SHMT2 inhibition affects the pro-
liferation and survival of cancer cells. Knockdown of
SHMT2 attenuated the growth of prostate cancer cells
(LNCaP, C4-2B, DU145, and PC3 cells) as well as various
cancer cell lines including glioblastoma line LN229 and
colon cancer cell lines HCT116 and SW480 (Fig. 6A)
following gene silencing by siRNA (Fig. S11). In addition,
treatment with a chemical inhibitor of SHMT2 (SHIN1)
inhibited the growth of LNCaP and C4-2B cells in a dose-
dependent manner and partially reduced the growth of
DU145 and PC3 cells (Fig. 6B). Interestingly,
SHIN1 significantly inhibited colony formation, a sign of
cancer growth, in LNCaP and DU145 cells (Fig. 6C, D).
Consistent with an increased sensitivity to cellular stress
after LONP1 and ClpP knockdown, we observed that
inhibition of SHMT2 enhanced cancer cell sensitivity to
stressors such as oxidative stress (H2O2, Fig. 6E) or star-
vation (low glucose, Fig. 6F). Furthermore, the reduction
of cell growth by simultaneous silencing of LONP1 and
ClpP was significantly more pronounced following SHIN1
treatment compared with that in separate silencing
experiments, whereas control siRNA-transfected cells
showed only a marginal effect following SHIN1 treatment
(Fig. 6G) These results demonstrate that SHMT2 is a key
substrate of LONP1 and ClpP in cancer growth and
resistance to cellular stress.
Discussion
To survive inhospitable tumor environments, tumor
cells activate stress adaptation pathways to buffer stress-
induced cytotoxicity. In turn, successful adaptation to
diverse cytotoxic stress provides cancer cells with survival
and proliferation advantages, leading to therapeutic
resistance, dormancy, and metastasis4. In these stress
adaptation processes, proteolytic removal of misfolded,
denatured, or oxidized proteins is important for the
integrity of subcellular organelles, especially mitochon-
dria, which possess their own proteolytic systems that are
evolutionarily conserved from bacterial cells30. However,
the detailed molecular mechanisms by which mitochon-
drial proteases coordinate their functions to maintain
proteostasis in cancer remain largely unknown. In this
study, we found evidence of functional crosstalk between
LONP1 and ClpP within the mitochondrial protein
(see figure on previous page)
Fig. 4 Mitochondrial protein quality control by ClpP and LONP1. A Mitochondrial proteins from LNCaP cells treated with control non-targeting
siRNA (siCtrl) or LONP1 (siLONP1) and ClpP-directed siRNA (siClpP) for 48 h were incubated with increasing concentrations of detergent (CHAPS),
separated by SDS gel electrophoresis, and visualized by SYPRO Ruby Stain. Aggregated and misfolded mitochondrial proteins are marked with
arrowheads. B Representative confocal images of mitochondrial morphology in LNCaP cells expressing mito-APEX. Twenty-four hours after
transfection, cells were fixed and stained with anti-V5 to detect mito-APEX expression. Mitotracker Deep Red staining was also used to visualize
mitochondria. Scale bar=10 μm. C LNCaP cells were transiently transfected with mito-APEX. Twenty-four hours later, cells were incubated with the
APEX substrate biotin-phenol and H2O2 for 1 min. Following cell lysis, biotinylated species were enriched by streptavidin pulldown. Western blot
analysis of biotinylated mitochondrial proteins before (input) and after (elution) streptavidin bead enrichment. D APEX-based mitochondrial
proteome analysis quantified by liquid chromatography-mass spectrometry for identification of direct target proteins for LONP1 or ClpP. Levels of 72
proteins were increased with a p < 0.05 and fold change ≥1.5 versus control siRNA in two independent experiments (n= 3). Upper, Venn diagram
showing the number of mitochondrial proteins upregulated by silencing of LONP1 or ClpP. Bottom, target proteins categorized according to Gene
Ontology enrichment analysis (DAVID). Red, common targets of LONP1 and ClpP; green, targets of LONP1; blue, targets of ClpP. E Fold increase in
mitochondrial proteins with p < 0.05 that were common targets of ClpP and LONP1. Fold enrichment was determined relative to LNCaP cells
transfected control siRNA. Data from two independent experiments are shown.
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quality control pathway required for cancer cell survival.
Depletion of LONP1 and ClpP led to the accumulation of
misfolded proteins and inhibited cell growth under
environmental stress conditions. Notably, as both pro-
teases share mitochondrial substrate targets, the absence
of both genes additively inhibited cell growth, disrupted
mitochondrial function, and increased oxidative stress,
leading to cancer cell death. Furthermore, co-expression
of both proteins at high levels in multiple tumor types was
associated with shortened patient survival, strongly sup-
porting a functional link between LONP1 and ClpP in
human cancer.
Fig. 5 ClpP and LONP1 cooperatively modulate SHMT2 folding. A–C LNCaP and DU145 cells were transfected with control non-targeting siRNA
(siCtrl) or LONP1 (siLONP1) and/or ClpP-directed siRNA (siClpP) for 72 h. A, B Total cell lysates were analyzed by western blotting. C Densitometric
quantification of SHMT2/α-tubulin bands. Mean ± SD (n= 3). *p < 0.01, **p < 0.001, ***p < 0.0001. D, E Mitochondria from DU145 cells transfected
with siCtrl or siLONP1 and/or siClpP for 72 h were mixed with increasing concentrations of CHAPS, and insoluble fractions were analyzed by western
blotting (D). E Densitometric quantification of bands in SHMT2 or ATP5B were normalized with bands in their VDAC. Data from three independent
experiments are shown. Mean ± SD (n= 3). *p < 0.01, **p < 0.001.
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Mitochondria have developed several stress response
mechanisms to maintain their homeostasis31–33,12. In
addition to selective removal of damaged mitochondria
through mitophagy, first-line defense mechanisms against
mitochondrial damage occur on a molecular level via
proteolytic machineries consisting of chaperones and
proteases. Apart from the stabilizing action of molecular
chaperones, the major defense mechanism against the
accumulation of damaged proteins is their specific
removal by proteolysis. To date, at least 15 mitochondrial
Fig. 6 SHMT2 inhibition reduces cancer cell proliferation and survival under stress conditions. A Cell lines were transfected with control non-
targeting siRNA (siCtrl) or SHMT2-directed siRNA (siSHMT2) for 48 h. Cell proliferation was measured by direct cell counting. Mean ± SD (n= 4). *p <
0.01, **p < 0.001, ***p < 0.0001. B Prostate cancer cell lines (LNCaP, C4–2B, DU145, and PC3) were treated with increasing concentrations (0–100 μM)
of SHIN1 for 48 h, Cell proliferation was measured by direct cell counting. Mean ± SD (n= 3). C, D LNCaP and DU145 cells were plated and treated
with or without SHIN1 (10 or 20 μM) for colony formation assay. Colonies were analyzed by crystal violet staining after 10 days and quantified (D).
Mean ± SD (n= 3). *p < 0.01, **p < 0.001. E, F DU145 cells were treated with or without SHIN1 (10 or 20 μM) for 24 h. Cells were incubated in (E) H2O2
(50 μM) or (F) low glucose (1 mM) for 24 h. Cell proliferation was measured by direct cell counting. Mean ± SD (n= 4). *p= 0.0210, ***p < 0.0001.
G DU145 cells were transfected with control non-targeting siRNA (siCtrl) or LONP1 (siLONP1) and/or ClpP-directed siRNA (siClpP) for 48 h. Cells were
incubated with SHIN1 (20 μM) for 24 h. Cell proliferation was measured by direct cell counting. Mean ± SD (n= 4). *p= 0.0032, **p < 0.001,
***p < 0.0001.
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proteases have been identified, including LONP1 and
ClpP, which are soluble AAA+mitochondrial proteases
in the mitochondrial matrix that contribute to the
maintenance of proteostasis18,30. However, the specific
substrates of each protease and their functions are still
largely unknown. There is increasing evidence that
LONP1 and ClpP are involved in cancer. For instance, the
silencing of LONP1 causes mitochondrial metabolic dys-
function, cellular senescence, and reduced tumor forma-
tion via remodeling of the oxidative phosphorylation
complex, whereas overexpression of LONP1 promotes
tumorigenesis14. In addition, cancer cells exposed to
stress stimuli, including hypoxia, exhibit increased
LONP1 expression associated with phosphorylation by
the Akt pathway, which enhances oxidative metabolism
and tumor cell metastatic competence34. Dysregulated
mitochondrial respiration capacity by ClpP inhibition
results in activation of cellular stress, reduced cell pro-
liferation, and impaired metastatic dissemination15. Inhi-
biting ClpP in leukemic cells leads to abnormal protein
accumulation and causes cell death22. Also, hyperactiva-
tion of ClpP activity induces abnormal mitochondrial
proteolysis and impairs mitochondrial function, leading to
cancer cell death18, suggesting that tight regulation of
protease activity is important for cancer and pointing
toward mitochondrial protease activity as a promising
therapeutic target for cancer.
Despite functional similarities between LONP1 and
ClpP in cancer, their regulatory mechanisms are largely
unknown. Here, we demonstrated that LONP1 and ClpP
work together to maintain mitochondrial proteostasis in
cancer. LONP1 and ClpP genes closely localized to
chromosomal region 19 and were co-expressed at high
levels in most human cancers. We revealed that the two
proteases share numerous target substrates that are cru-
cial components of mitochondrial functions, including
oxidative phosphorylation, the TCA cycle, and amino acid
and lipid metabolism. We found that LONP1 and ClpP
cooperate to maintain protein quality and the activity of
target substrates, which may support cancer cell pro-
liferation and survival from cellular stress. Accordingly,
inhibition of both LONP1 and ClpP potently reduced
cancer cell viability with concomitantly induced mito-
chondrial bioenergetics dysfunction as evidenced by
phosphorylation of AMPK and activation of autophagy.
Furthermore, inhibition of both genes additively reduced
cell growth and survival under harsh environmental
conditions such as oxidative stress and nutrient depriva-
tion. As an adaptive stress response is associated with
aggressive tumor activity, including metastasis and drug
resistance, co-targeting both proteases could be an
effective therapeutic strategy for advanced cancer.
SHMT2 is the enzyme that converts serine to glycine
in one-carbon metabolism, which provides essential
substrates for nucleic acid and protein metabolism35,36.
SHMT2 is highly upregulated in diverse cancer types,
correlated with poor outcomes, and may support tumor
aggressiveness by enhancing mitochondrial functions,
including redox balance and nucleotide synthesis27,29,37.
In particular, SHMT2 emerged as a key enzyme for the
metabolic adaptation of cancer against stress conditions.
SHMT2 is required for mitochondrial respiration by
supporting oxygen consumption, and an elevated level of
SHMT2 reduces mitochondrial pyruvate metabolism and
limits oxygen consumption to adapt to the stress28,38.
Furthermore, the depletion of SHMT2 impaired mito-
chondrial functions and showed higher cellular ROS levels
under metabolic stress conditions such as hypoxia and
serine/glycine starvation28. In our study, we found that
SHMT2 is a common target substrate of LONP1 and
ClpP for cancer cell survival. LONP1 or ClpP inhibition
increased unfolding of SHMT2. Consistent with the cel-
lular effects of LONP1 and ClpP inhibition, depletion of
SHMT also reduced cancer cell growth and survival under
cytotoxic stress conditions. Furthermore, depletion of
LONP1 and ClpP increased cell sensitivity to an SHMT2
inhibitor, suggesting that SHMT2 is a key substrate in the
LONP1- and ClpP-mediated proteostasis network and
that its protein quality control by mitochondrial proteases
may promote cancer cell survival and progression.
In summary, our study reveals a functional relationship
between two mitochondrial proteases LONP1 and ClpP in
maintaining mitochondrial proteostasis in cancer. The
coordinated regulation of these two proteases, which are
commonly altered in different human cancers, appears to
protect mitochondrial functions and thereby promote can-
cer cell growth and survival from cellular stresses. Our
results also suggest that targeting the mitochondrial pro-
teostasis network could be an effective therapeutic strategy
for cancer. However, as mitochondrial proteostasis is tightly
regulated by the coordination of diverse machineries, further
studies are required to fully understand the exact mechan-
isms that regulate mitochondria quality control and their
interconnection among proteostasis modules to develop an
effective therapeutic strategy for cancer treatment.
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